Unity Biotechnology, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Anirvan Ghosh
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 285 East Grand Avenue South San Francisco CA United States of America 94080
- IPO Date
- May 3, 2018
- CIK
- 0001463361
- Website
- unitybiotechnology.com
- Similar Companies
- Business
- Unity Biotechnology, Inc. operates as a biotechnology entity dedicated to the research and development of novel therapies aimed at slowing, arresting, or potentially reversing the progression of age-related illnesses. The company's primary therapeutic focus centers on the selective elimination or modulation of senescent cells, a key biological mechanism implicated in aging and associated conditions. Its lead investigational compound, UBX1325, a small molecule inhibitor, has been undergoing Phase 2b clinical evaluation for the treatment of age-related ophthalmologic disorders such as diabetic macular edema (DME) and age-related macular degeneration (AMD). Recent findings from the ASPIRE Phase 2b study, reported in early to mid-2025, indicated UBX1325 achieved vision improvements comparable to existing treatments in certain aspects and within specific patient groups, though it did not consistently meet all statistical non-inferiority endpoints. Following these results, Unity Biotechnology has announced a strategic re-evaluation, including efforts to reduce operational expenditure and explore various strategic alternatives, such as potential sales or partnerships, while focusing resources on its core ophthalmology programs. Earlier-stage pipeline assets, including UBX1967 for other eye conditions, UBX2050 as an anti-Tie2 agonist, and UBX2089 targeting neurological indications, have been deprioritized or paused to streamline development efforts. Originally established as Forge, Inc., the company adopted the name Unity Biotechnology, Inc. in January 2015, following its incorporation in 2009. The firm is headquartered in South San Francisco, California. It went public on the Nasdaq exchange in 2018, however, in July 2025, the company was delisted from Nasdaq and its shares transitioned to trading on the OTC Markets under a new ticker symbol.
UBX Tanzania Deepens Partnership with ACI Worldwide to Power the Next Phase of the Nation's Digital Economy
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
UNITY Biotechnology Reports Granting of New Employment Inducement Award
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer
All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss